ThromboGenics N.V. - Business Update (ion of this is that spontaneous bleeding...)

ThromboGenics N.V. - Business Update

Date:5/13/2008

ion of this is that spontaneous bleeding events, which are a potential unwanted side effect if Factor VIII is completely inhibited, should not occur. Hence, there would be no need for the monitoring of coagulation parameters in the patient.

ThromboGenics is developing TB-402 in collaboration with BioInvent International.

In comparison to other current anticoagulants that require daily dosage, TB-402 has a prolonged half-life that will allow for a single-dose treatment in orthopaedic surgery patients and/or once-a-month administration for long-term stroke prevention in atrial fibrillation (AF).

Staphylokinase

- Initiation of Phase III by Bharat Biotech International Ltd in India.

ThromboGenics has entered into a partnership with Bharat Biotech to continue the clinical development and commercialization of THR-100. This novel variant of Recombinant Staphylokinase is initially being developed by Bharat in India for the treatment of acute myocardial infarction (AMI), or heart attack. Given the commercial strengths of Bharat in this market and the clinical advantages of THR-100, it is hoped that this novel product will quickly become the market leader for the treatment of heart attacks in India. It is currently anticipated that THR-100 Phase III will be started in India in the third quarter.

Patrik De Haes, COO of ThromboGenics, commenting on today's release said, "ThromboGenics is confident that 2008 will be a transformational year for the Company. The important clinical milestones that we expect to achieve will further highlight the attractiveness of our clinical pipeline of innovative vascular biopharmaceuticals. These milestones will also provide us with a platform for signing partnership deals, which are an important element of our strategy to develop ThromboGenics into an important player in the areas of vascular disease, eye disease and cancer."

ThromboGenics will provide a further update when the Company reports its
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
11. DuPont Leaders Brief Investors on Agriculture Businesses

Post Your Comments:

ThromboGenics N.V. - Business Update(ion of this is that spontaneous bleeding...)